Shattuck Labs (NASDAQ:STTK) Issues Earnings Results

Shattuck Labs (NASDAQ:STTK) posted its quarterly earnings data on Thursday. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports. The company had revenue of $1.00 million for the quarter.

Shattuck Labs Trading Down 3.9%

STTK traded down $0.08 on Thursday, reaching $1.96. The company had a trading volume of 108,901 shares, compared to its average volume of 249,310. The company has a fifty day moving average of $1.97 and a 200-day moving average of $1.29. The company has a market capitalization of $93.88 million, a P/E ratio of -1.62 and a beta of 1.88. Shattuck Labs has a one year low of $0.69 and a one year high of $2.70.

Analyst Ratings Changes

STTK has been the topic of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, August 14th. Wall Street Zen raised shares of Shattuck Labs from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Leerink Partners dropped their target price on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Thursday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, Wedbush initiated coverage on shares of Shattuck Labs in a report on Monday, September 8th. They set an “outperform” rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $3.00.

Insider Activity

In other Shattuck Labs news, Director Mona Ashiya acquired 6,306,127 shares of Shattuck Labs stock in a transaction dated Monday, August 25th. The stock was bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of Shattuck Labs stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its position in shares of Shattuck Labs by 27.6% during the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after purchasing an additional 55,687 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock worth $229,000 after buying an additional 278,576 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Shattuck Labs in the first quarter worth about $81,000. Bridgeway Capital Management LLC boosted its holdings in shares of Shattuck Labs by 147.5% in the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after buying an additional 55,000 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Shattuck Labs in the second quarter worth about $44,000. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.